These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 25840679)

  • 1. Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer.
    Verso M; Agnelli G; Prandoni P
    Intern Emerg Med; 2015 Sep; 10(6):651-6. PubMed ID: 25840679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
    PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
    Proietti M; Lip GY
    Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
    Voigtlaender M; Langer F
    Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism.
    Robert-Ebadi H; Righini M
    Ther Umsch; 2016; 73(10):618-625. PubMed ID: 28045360
    [No Abstract]   [Full Text] [Related]  

  • 7. [Not Available].
    Själander S; Själander A
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
    [No Abstract]   [Full Text] [Related]  

  • 8. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New anticoagulants for the treatment of venous thromboembolism.
    Fernandes CJ; Alves Júnior JL; Gavilanes F; Prada LF; Morinaga LK; Souza R
    J Bras Pneumol; 2016 Apr; 42(2):146-54. PubMed ID: 27167437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of New Oral Anticoagulants (NOACs) in Cancer Patients.
    Ravikumar R; Lim CS; Davies AH
    Adv Exp Med Biol; 2017; 906():137-148. PubMed ID: 27620312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials.
    Rojas-Hernandez CM; Oo TH
    Drugs; 2019 Apr; 79(6):621-631. PubMed ID: 30905033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials.
    Loffredo L; Violi F; Perri L
    Int J Cardiol; 2016 Jun; 212():255-8. PubMed ID: 27057930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patients.
    Pathak R; Giri S; Karmacharya P; Aryal MR; Poudel DR; Ghimire S; Jehangir A; Shaikh B; Rettew A; Donato AA
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):934-9. PubMed ID: 26258674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New oral anticoagulants for acute venous thromboembolism.
    Med Lett Drugs Ther; 2014 Jan; 56(1433):3-4. PubMed ID: 24419296
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
    Imberti D; Pomero F; Benedetti R; Fenoglio L
    Intern Emerg Med; 2016 Oct; 11(7):895-900. PubMed ID: 27550399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism management: where do novel anticoagulants fit?
    Spyropoulos AC; Turpie AG
    Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
    Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
    J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended use of sulodexide, apixaban, rivaroxaban and dabigatran in venous thromboembolism: indirect comparison of clinical trials.
    Tomkowski W; Kuca P; Bignamini AA; Andreozzi GM
    Int Angiol; 2017 Oct; 36(5):496-497. PubMed ID: 28641408
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.